Recent Advances in CAR-Based Solid Tumor Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is effective for blood cancers but faces challenges in solid tumors, including the immunosuppressive tumor microenvironment (TME), poor infiltration, and lack of specific antigens.
• Recent CAR-T advancements like co-stimulatory domains and armored CAR-T cells show potential but require further development.
• Natural killer (NK) cells and macrophages (M) are emerging as alternative CAR-engineered platforms for solid tumor immunotherapy due to their unique properties.

Purpose of the Study:

• To review recent advancements in engineered immune cell-based cancer immunotherapies for solid tumors.
• To discuss the challenges and future perspectives of CAR-T, CAR-NK, and CAR-M therapies.
• To summarize ongoing clinical trials evaluating the safety and efficacy of these engineered immune cells.

Main Methods:

• Review of recent scientific literature on CAR-T, CAR-NK, and CAR-M cell therapies.
• Analysis of advancements in CAR cell design and engineering strategies.
• Compilation of data from ongoing clinical trials for engineered immune cells targeting solid tumors.

Main Results:

• CAR-T cells demonstrate efficacy in hematological malignancies but struggle with solid tumors.
• CAR-NK cells offer 'off-the-shelf' availability and low toxicity, showing clinical improvements.
• CAR-M cells possess potential due to macrophages' ability to infiltrate the TME of solid tumors.

Conclusions:

• Engineered immune cells, particularly CAR-NK and CAR-M, present promising therapeutic avenues for solid tumors.
• Overcoming TME-related challenges and identifying tumor-specific antigens remain critical for enhancing efficacy.
• Ongoing clinical trials are crucial for validating the safety and effectiveness of these advanced immunotherapies.